Patheon NV (PTHN) Given Consensus Recommendation of “Buy” by Analysts

Patheon NV (NASDAQ:PTHN) has been given an average recommendation of “Buy” by the thirteen ratings firms that are currently covering the firm. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $31.30.

Several analysts have recently weighed in on PTHN shares. Zacks Investment Research lowered shares of Patheon NV from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 22nd. Jefferies Group LLC reiterated a “buy” rating and issued a $32.00 price objective (down previously from $33.00) on shares of Patheon NV in a research note on Friday, March 17th. Finally, Robert W. Baird lowered shares of Patheon NV from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $34.00 to $28.00 in a research note on Friday, March 17th.

A number of institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new position in Patheon NV during the third quarter worth about $91,321,000. TimesSquare Capital Management LLC purchased a new position in Patheon NV during the third quarter worth about $50,137,000. Samlyn Capital LLC purchased a new position in Patheon NV during the third quarter worth about $40,553,000. BlackRock Advisors LLC bought a new position in shares of Patheon NV during the third quarter worth $36,634,000. Finally, Citadel Advisors LLC bought a new position in shares of Patheon NV during the third quarter worth $31,226,000.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.themarketsdaily.com/2017/04/21/patheon-nv-pthn-receives-average-rating-of-buy-from-analysts-updated.html.

Shares of Patheon NV (NASDAQ:PTHN) traded down 1.89% during midday trading on Friday, hitting $24.98. 407,246 shares of the company’s stock traded hands. The company has a 50 day moving average price of $27.68 and a 200 day moving average price of $28.20. Patheon NV has a 1-year low of $23.72 and a 1-year high of $32.95. The firm has a market capitalization of $3.63 billion and a price-to-earnings ratio of 40.55.

Patheon NV (NASDAQ:PTHN) last released its quarterly earnings results on Thursday, March 16th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by $0.08. The business had revenue of $457.40 million for the quarter, compared to analysts’ expectations of $463.39 million. During the same period last year, the firm posted ($0.08) EPS. The business’s revenue was up 12.7% on a year-over-year basis. Equities analysts anticipate that Patheon NV will post $1.14 earnings per share for the current year.

Patheon NV Company Profile

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.

5 Day Chart for NASDAQ:PTHN

Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply